Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sangeeta Ray is active.

Publication


Featured researches published by Sangeeta Ray.


Cancer Research | 2016

Abstract 4206: A dual-motif CAIX inhibitor, [64Cu]XYIMSR-06, for PET imaging of clear cell renal cell carcinoma

Il Minn; Soo Min Koo; Hye Soo Lee; Mary E. Brummet; Steven P. Rowe; Michael A. Gorin; Polina Sysa-Shah; William D. Lewis; Hye-Hyun Ahn; Yuchuan Wang; Sangeeta Ray; Ronnie C. Mease; Sridhar Nimmagadda; Mohamad E. Allaf; Martin G. Pomper; Xing Yang

Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of clear cell renal cell carcinomas (ccRCCs), the most common renal cancer. CAIX is also a surrogate marker of hypoxic tumors for various human cancers; however, a clinically viable molecular imaging agent targeting CAIX is not available. We have synthesized and performed in vitro and in vivo evaluation of a dual-motif, low-molecular-weight inhibitor of CAIX, [ 64 Cu] XYIMSR-06, for imaging CAIX expression on ccRCC tumors using positron emission tomography (PET). [ 64 Cu] XYIMSR-06 was synthesized in two steps from reported dual-motif precursor 1. Upon radiolabeling, [ 64 Cu] XYIMSR-06 was evaluated in immunocompromised mice bearing CAIX-expressing SK-RC-52 tumors for in vivo PET imaging and biodistribution. [ 64 Cu] XYIMSR-06 was generated in radiochemical yields of 51.0 ± 4.5% (n = 5) and specific radioactivity of 6.0 GBq/μmol (170Ci/mmol ± 70, n = 5). Tumor could be visualized on PET images by 1 h post-injection with high tumor-to-background levels achieved within 24 h. Biodistribution studies of [ 64 Cu] XYIMSR-06 demonstrated a maximum tumor uptake of 19.3 ± 4.51% injected dose per gram of radioactivity at 4 h. Tumor-to- blood, muscle and kidney ratios were 129.6 ± 18.8, 84.3 ± 21.0 and 2.1 ± 0.26, respectively, at 8 h post-injection. At 24 h, a tumor-to-kidney ratio of 7.1±2.5 was achieved. These findings represent increased tumor-to-background ratios at the indicated times relative to previously reported CAIX-targeted imaging agents. [ 64 Cu] XYIMSR-06 is a promising candidate for PET imaging of CAIX expressing tumors, especially ccRCC. Citation Format: IL MINN, Soo Min Koo, Hye Soo Lee, Mary Brummet, Steven P. Rowe, Michael A. Gorin, Polina Sysa-Shah, William D. Lewis, Hye-Hyun Ahn, Yuchuan Wang, Sangeeta Ray, Ronnie C. Mease, Sridhar Nimmagadda, Mohamad E. Allaf, Martin G. Pomper, Xing Yang. A dual-motif CAIX inhibitor, [64Cu]XYIMSR-06, for PET imaging of clear cell renal cell carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4206.


Archive | 2008

PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER

Sachin S. Chandran; Sangeeta Ray; Martin G. Pomper; Samuel R. Denmeade; Ronnie C. Mease


Archive | 2016

COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI)

Xing Yang; Xiaolei Song; Sangeeta Ray; Martin G. Pomper; Michael T. McMahon


Archive | 2015

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

Sangeeta Ray; Martin G. Pomper; Thomas J. Meade; Ronnie C. Mease; Ying Chen; Xing Yang; Matthew Rotz


Archive | 2012

HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA) AND USES THEREOF

Martin G. Pomper; Sangeeta Ray; Ronnie C. Mease; Hassan Shallal


Archive | 2012

THERANOSTIC IMAGING AGENTS AND METHODS OF USE

Martin G. Pomper; Zaver M. Bhujwalla; Zhihang Chen; Cong Li; Sridhar Nimmagadda; Marie-France Penet; Sangeeta Ray


The Journal of Nuclear Medicine | 2011

99mTc-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer

Sangeeta Ray; Mrudula Pullambhatla; Alexander Falk; Youngjoo Byun; Catherine A. Foss; Sridhar Nimmagadda; James Fox; Ronnie C. Mease; Martin G. Pomper


The Journal of Nuclear Medicine | 2018

Pharmacokinetic variability of 225Ac and 213Bi from vector labeled 225Ac cancer therapy as a function of vector type (antibody vs. small molecule)

Anders Josefsson; Jessie Nedrow; Sangeeta Ray; Frank Bruchertseifer; Alfred Morgenstern; Martin G. Pomper; George Sgouros; R. Hobbs


Archive | 2016

68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS

Martin G. Pomper; Ronnie C. Mease; Sangeeta Ray


Archive | 2016

NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY

Martin G. Pomper; Ronnie C. Mease; Sangeeta Ray; Ying Chen; Xing Yang

Collaboration


Dive into the Sangeeta Ray's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xing Yang

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ying Chen

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anders Josefsson

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge